Scholarlink

Objective <p>To evaluate the efficacy and safety of duloxetine in treatment of osteoarthritis compared with placebo.</p> Method <p>We conducted a comprehensive search for pertinent randomized controlled trials (RCTs) across multiple databases, including PubMed, Embase, Scopus, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and Google scholar. These selected RCTs aimed to assess the effectiveness and safety of duloxetine versus a placebo in the management of osteoarthritis (OA). We computed the mean difference (MD) for continuous outcome measures and calculated the risk ratio (RR) for dichotomous outcome measures.</p> Results <p>Data from 10 RCT including 2294 participants comparing duloxetine and placebo were pooled. Duloxetine showed improvement in BPI-S (Brief Pain Inventory-Severity)MD =  – 0.66; 95% CI, [– 0.75, – 0.57], BPI-I (Brief Pain Inventory-Interference)MD =  – 0.59; 95% CI [– 0.66, – 0.52], WOMAC (Western Ontario and McMaster Universities Arthritis Index) pain sub scale scores SMD =  – 2.56; 95% CI, [– 4.24, – 0.89] <i>P</i> = 0.003; physical function MD =  – 4.59; 95% CI, [– 5.83, – 3.34] <i>P</i> &lt; 0.00001; SF 36 (Short Form) Physical function MD = 1.56; 95% CI, [0.14, 2.97] <i>P</i> = 0.03 and patients global impressions scores SMD =  – 0.47; 95% CI, [– 0.62, – 0.32]. Duloxetine resulted in higher number of treatment emergent adverse events RR = 1.34; 95% CI, [1.12,1.61] <i>P</i> = 0.002; and discontinuations RR = 2.54; 95%, CI, [1.89, 3.42] <i>P</i> &lt; 0.00001. However duloxetine was no different from placebo in improving stiffness and in terms of incidence of serious adverse effects.</p> Conclusion <p>Duloxetine demonstrates effectiveness in addressing chronic pain and mitigating the decline in physical function associated with knee osteoarthritis (OA), while maintaining a reasonable level of tolerable adverse events. However, it does not offer a distinct advantage in alleviating joint stiffness.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Navigating the Efficacy and Safety Landscape of Duloxetine in Osteoarthritis Management: A Meta-Analysis of Randomized Controlled Trials

  • 期刊论文

  • 发表日期：

    2025年7月31日

查看全文
  • Baibhav Bhandari,
  • Kanchan Bisht,
  • Gaurav Purohit,
  • Shiwam Gupta,
  • Girish Kumar Singh,
  • Sonal Goyal,
  • Pradeep Atter,
  • Ajit Kumar,
  • Praveen Talawar

摘要

Objective

To evaluate the efficacy and safety of duloxetine in treatment of osteoarthritis compared with placebo.

Method

We conducted a comprehensive search for pertinent randomized controlled trials (RCTs) across multiple databases, including PubMed, Embase, Scopus, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and Google scholar. These selected RCTs aimed to assess the effectiveness and safety of duloxetine versus a placebo in the management of osteoarthritis (OA). We computed the mean difference (MD) for continuous outcome measures and calculated the risk ratio (RR) for dichotomous outcome measures.

Results

Data from 10 RCT including 2294 participants comparing duloxetine and placebo were pooled. Duloxetine showed improvement in BPI-S (Brief Pain Inventory-Severity)MD =  – 0.66; 95% CI, [– 0.75, – 0.57], BPI-I (Brief Pain Inventory-Interference)MD =  – 0.59; 95% CI [– 0.66, – 0.52], WOMAC (Western Ontario and McMaster Universities Arthritis Index) pain sub scale scores SMD =  – 2.56; 95% CI, [– 4.24, – 0.89] P = 0.003; physical function MD =  – 4.59; 95% CI, [– 5.83, – 3.34] P < 0.00001; SF 36 (Short Form) Physical function MD = 1.56; 95% CI, [0.14, 2.97] P = 0.03 and patients global impressions scores SMD =  – 0.47; 95% CI, [– 0.62, – 0.32]. Duloxetine resulted in higher number of treatment emergent adverse events RR = 1.34; 95% CI, [1.12,1.61] P = 0.002; and discontinuations RR = 2.54; 95%, CI, [1.89, 3.42] P < 0.00001. However duloxetine was no different from placebo in improving stiffness and in terms of incidence of serious adverse effects.

Conclusion

Duloxetine demonstrates effectiveness in addressing chronic pain and mitigating the decline in physical function associated with knee osteoarthritis (OA), while maintaining a reasonable level of tolerable adverse events. However, it does not offer a distinct advantage in alleviating joint stiffness.